Fifty-two percent of endocrinologists would start rhGH with a similar dose used in patients with hypopituitarism, 40% would titrate the GH dose according to serum IGF-I levels, 28% would start at a lower dose, and 8% would decide the dose based on the histology of the tumor (Q17 multiple choice). The gene discussed is IGF1; the disease is neoplasm.